Head-To-Head Survey: Seaport Therapeutics (SPTX) vs. Its Rivals

Seaport Therapeutics (NASDAQ:SPTX) is one of 907 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Seaport Therapeutics to similar companies based on the strength of its profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Institutional and Insider Ownership

32.8% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Seaport Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seaport Therapeutics	N/A	N/A	N/A
Seaport Therapeutics Competitors	-2,303.79%	-221.76%	-17.81%

Valuation and Earnings

This table compares Seaport Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Seaport Therapeutics	N/A	-$74.88 million	-1.99
Seaport Therapeutics Competitors	$3.50 billion	$3.13 billion	541.39

Seaport Therapeutics’ peers have higher revenue and earnings than Seaport Therapeutics. Seaport Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Seaport Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seaport Therapeutics	2	3	5	0	2.30
Seaport Therapeutics Competitors	7693	13651	25519	992	2.41

Seaport Therapeutics presently has a consensus price target of $38.40, indicating a potential upside of 59.47%. As a group, “Pharmaceuticals” companies have a potential upside of 27.87%. Given Seaport Therapeutics’ higher possible upside, analysts clearly believe Seaport Therapeutics is more favorable than its peers.

Summary

Seaport Therapeutics peers beat Seaport Therapeutics on 8 of the 12 factors compared.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.